FINWIRES · TerminalLIVE
FINWIRES

$CI

24 stories mentioning CIUpdated 2d ago

Every FINWIRES story that references CI, newest first.

Insider Trading

Cigna Insider Sold Shares Worth $5,369,584, According to a Recent SEC Filing

Nicole S Jones, EVP, Chief Administrative Officer and Chief Human Resources Officer, on August 04, 2026, sold 19,436 shares in Cigna (CI) for $5,369,584. Following the Form 4 filing with the SEC, Jones has control over a total of 28,707 common shares of the company, with 27,256 shares held directly and 1,451 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1739940/000173994026000067/xslF345X05/wk-form4_1786048270.xml

$CI
Research

Jefferies Downgrades Cigna Group to Hold From Buy, Adjusts Price Target to $307 From $336

Cigna Group (CI) has an average rating of overweight and mean price target of $341.17, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)

$CI
Wire

Cigna's Specialty Momentum Supports Q2 Results Despite Pharmacy Headwinds, UBS Says

Cigna Group's (CI) Evernorth health-services unit recorded stronger-than-expected adoption of newer specialty generics in Q2, with use exceeding 80% for recent launches, UBS Securities said Friday in a report.This was partly offset by softer pharmacy results as GLP-1 prescriptions moderated amid declining coverage levels and slower utilization growth, the report said.Evernorth closed the 2026 selling season with retention above 97%, and early indicators for 2027 point to similarly strong levels, UBS said.Cigna's new rebate-free Signature model is drawing client interest, and management remains confident the pharmacy business can return to 4% margins under the new structure, the report said.UBS maintained its buy rating on Cigna stock and its $400 price target.Price: $282.70, Change: $-4.96, Percent Change: -1.72%

$CI
Wire

Cigna's Cigna Healthcare Expanding AI-Backed Support

Cigna's (CI) Cigna Healthcare said Thursday it is expanding its care management programs with AI-backed capabilities to help identify clients who would benefit from earlier support.The move will allow 20% more clients with emerging, complex or chronic health needs to get clinical support earlier and will decrease medical costs by $200 million over three years, the company said.Price: $284.95, Change: $+0.10, Percent Change: +0.04%

$CI
Wire

Update: Market Chatter: DOJ Expands Antitrust Probe Into Claritev

(Updates with Claritev's response in the fourth paragraph.)The US Justice Department recently sent civil investigative demands, which are similar to subpoenas, to lawyers for a group of hospitals and doctor groups suing Claritev (CTEV) for alleged antitrust violations, Bloomberg reported Tuesday, citing people with knowledge of the matter.The lawsuits accuse the healthcare technology firm of conspiring with UnitedHealth Group (UNH), CVS Health's (CVS) Aetna and Cigna Group (CI) and other health insurers to lower reimbursements for out-of-network services, the report said."We decline to comment on any matters before the DOJ, according to longstanding policy," a DOJ spokesperson told. "However, we can affirm that under the Trump Administration this DOJ will continue to prioritize affordability for all Americans across our economy.""Claritev previously disclosed both the closure of the DOJ's criminal antitrust investigation and the company's receipt of a civil investigative demand ("CID")," a Claritev spokesperson said in an emailed statement to. "The CID does not make findings or allegations, and Claritev is fully cooperating with the DOJ in providing the information it seeks."(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)Price: $28.59, Change: $-1.26, Percent Change: -4.21%

$CI$CTEV$CVS$UNH
Wire

Update: Market Chatter: DOJ Expands Antitrust Probe Into Claritev

(Update with the Justice Department's response to a request for comment in the third paragraph.)The US Justice Department recently sent civil investigative demands, which are similar to subpoenas, to lawyers for a group of hospitals and doctor groups suing Claritev (CTEV) for alleged antitrust violations, Bloomberg reported Tuesday, citing people with knowledge of the matter.The lawsuits accuse the healthcare technology firm of conspiring with UnitedHealth Group (UNH), CVS Health's (CVS) Aetna and Cigna Group (CI) and other health insurers to lower reimbursements for out-of-network services, the report said."We decline to comment on any matters before the DOJ, according to longstanding policy," a DOJ spokesperson told. "However, we can affirm that under the Trump Administration this DOJ will continue to prioritize affordability for all Americans across our economy."Claritev didn't immediately reply to a request for comment from.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)Price: $26.49, Change: $-3.35, Percent Change: -11.23%

$CI$CTEV$CVS$UNH
Wire

Market Chatter: DOJ Expands Antitrust Probe Into Claritev

The US Justice Department recently sent civil investigative demands, which are similar to subpoenas, to lawyers for a group of hospitals and doctor groups suing Claritev (CTEV) for alleged antitrust violations, Bloomberg reported Tuesday, citing people with knowledge of the matter.The lawsuits accuse the healthcare technology firm of conspiring with UnitedHealth Group (UNH), CVS Health's (CVS) Aetna and Cigna Group (CI) and other health insurers to lower reimbursements for out-of-network services, the report said.Claritev and the Justice Department didn't immediately reply to requests for comment from.(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)Price: $27.91, Change: $-1.93, Percent Change: -6.47%

$CI$CTEV$CVS$UNH
Wire

UnitedHealth, CVS, Cigna Seen Benefiting From Utilization Trends, AI Upside, Morgan Stanley Says

UnitedHealth (UNH), CVS Health (CVS) and Cigna (CI) are among the managed-care companies that could benefit from improving utilization trends and potential artificial intelligence-driven efficiency gains across the healthcare system, Morgan Stanley said in a note Thursday.The firm said early signs of softer utilization have supported recent gains in managed-care stocks. The group has delivered a series of medical-loss-ratio beats in Q1 and some companies raising guidance. However, it noted that investors are still awaiting clearer confirmation of underlying trends and utilization signals remaining mixed ahead of Q2 results.AI adoption is increasingly embedded across managed-care operations, including prior authorization, call centers, provider portals, care management, pharmacy utilization and payment integrity.Morgan Stanley said UnitedHealth stands out as a leading "AI enabler," particularly through Optum Insight initiatives, which support both efficiency gains and potential revenue upside.The firm's scenario analysis assumes 0.5% to 2.0% AI-driven insurance margin expansion, which could translate into an illustrative 18% to 71% EPS upside across managed-care companies. It added that administrative workflows, particularly prior authorization, remain key areas of automation potential.Morgan Stanley boosted its price targets on UnitedHealth, CVS Health, Elevance Health (ELV), Centene (CNC), Molina Healthcare (MOH), and Humana (HUM).Price: $399.90, Change: $+22.90, Percent Change: +6.07%

$CI$CNC$CVS$ELV$HUM$MOH$UNH
Sectors

Sector Update: Healthcare Stocks Decline Late Afternoon

Healthcare stocks were lower late Tuesday afternoon, with the NYSE Healthcare Index shedding 0.7% and the State Street Health Care Select Sector SPDR ETF (XLV) decreasing 0.7%.The iShares Biotechnology ETF (IBB) rose 0.5%.In corporate news, Cigna (CI) shares fell 1.6% after Barclays downgraded the stock to equalweight from overweight, and lowered its price target to $304 from $310.Brazil on Tuesday cleared pharmaceutical company EMS to sell the country's first generic version of Novo Nordisk's (NVO) Ozempic shot, Bloomberg reported. EMS plans to sell the generic version, called Ozivy, for 30% less than Ozempic, and it expects it to hit the market within 30 days, the report said. Novo shares were down 1.5%.Eli Lilly (LLY) said it has struck deals to buy three vaccine developers in all-cash deals with a combined value of up to $3.83 billion to build its infectious disease portfolio. Lilly shares rose 0.5%.CG Oncology (CGON) shares fell 3.8% after the firm said that Ambaw Bellete, its president and chief operating officer, will exit the company, effective June 30.

$CGON$CI$LLY$NVO
Sectors

Sector Update: Healthcare

Healthcare stocks were lower late Tuesday afternoon, with the NYSE Healthcare Index shedding 0.7% and the State Street Health Care Select Sector SPDR ETF (XLV) decreasing 0.7%.The iShares Biotechnology ETF (IBB) rose 0.5%.In corporate news, Cigna Group (CI) shares fell 1.8% after Barclays downgraded the stock to equalweight from overweight, and lowered its price target to $304 from $310.

$CI
Wire

Cigna Group Shares Fall After Barclays Downgrade

Cigna Group (CI) shares were down about 2% in afternoon trading on Tuesday after Barclays downgraded the stock to equalweight from overweight, and lowered its price target to $304 from $310.Trading volume stood at more than 720,000 shares, compared with a daily average of about 1.7 million.Price: $280.70, Change: $-5.54, Percent Change: -1.94%

$CI
Sectors

Sector Update: Healthcare Stocks Mixed Late Afternoon

Healthcare stocks were mixed late Wednesday afternoon, with the NYSE Healthcare Index up 0.1% and the State Street Health Care Select Sector SPDR ETF (XLV) down 0.2%.The iShares Biotechnology ETF (IBB) rose 1.9%.In corporate news, Cigna (CI) shares fell 2.5% after Deutsche Bank downgraded the stock to hold from buy and cut its price target to $302 from $303.Medtronic (MDT) said Wednesday it is planning to acquire medical technology firm SPR Therapeutics for an upfront cash payment of about $650 million. Shares were down 0.8%.Personalis (PSNL) shares jumped 12% after the company said its NeXT personal minimal residual disease test has been approved for expanded coverage by the US Centers for Medicare & Medicaid Services' Molecular Diagnostic Services Program.Immunovant (IMVT) shares surged 35% after the firm said its cash and cash equivalents were about $902.1 million as of March 31, providing runway for announced indications through the potential commercial launch of IMVT-1402 in Graves' disease.

$CI$IMVT$MDT$PSNL
Sectors

Sector Update: Healthcare

Healthcare stocks were lower late Wednesday afternoon, with the NYSE Healthcare Index and the State Street Health Care Select Sector SPDR ETF (XLV) each decreasing about 0.1%.The iShares Biotechnology ETF (IBB) rose 1.9%.In corporate news, Cigna (CI) shares fell 2.2% after Deutsche Bank downgraded the company's stock to hold from buy and adjusted its price target to $302 from $303.

$CI
Wire

Cigna Shares Fall After Deutsche Bank Downgrade

Cigna (CI) shares were down 2.3% in Wednesday trading after Deutsche Bank downgraded the company's stock to hold from buy and adjusted its price target to $302 from $303.Trading volume stood at about 552,000 shares compared with a daily average of over 1.7 million.Price: $284.26, Change: $-7.02, Percent Change: -2.41%

$CI
Research

Deutsche Bank Downgrades Cigna to Hold From Buy, Adjusts PT to $302 From $303

Cigna Group (CI) has an average rating of Buy and mean price target of $340.48, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)

$CI
Insider Trading

Cigna Insider Sold Shares Worth $59,114,186, According to a Recent SEC Filing

David Cordani, Director, Chairman & CEO, on May 12, 2026, sold 201,878 shares in Cigna (CI) for $59,114,186. Following the Form 4 filing with the SEC, Cordani has control over a total of 634,873 common shares of the company, with 34,337 shares held directly and 600,536 controlled indirectly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1739940/000173994026000044/xslF345X05/wk-form4_1778791641.xml

$CI
Wire

Baird Adjusts Cigna Price Target to $337 From $306

Cigna Group (CI) has an average rating of Buy and mean price target of $340.96, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)Price: $284.03, Change: $-6.55, Percent Change: -2.25%

$CI
Wire

Barclays Adjusts Cigna Price Target to $310 From $303

Cigna Group (CI) has an average rating of Buy and mean price target of $340.96, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)Price: $284.03, Change: $-6.55, Percent Change: -2.25%

$CI
Wire

Mizuho Securities Adjusts Cigna Price Target to $330 From $325

Cigna Group (CI) has an average rating of Buy and mean price target of $340.96, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)Price: $284.12, Change: $-6.46, Percent Change: -2.22%

$CI
Wire

Cantor Fitzgerald Adjusts Cigna Price Target to $340 From $325

Cigna Group (CI) has an average rating of Buy and mean price target of $340.96, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://finwires.com/en/contact)Price: $284.21, Change: $-6.37, Percent Change: -2.19%

$CI

Showing 1-20 of 24

Track with the FINWIRES app suite

FolioX
FolioX
Track CI in your portfolio
WheelAI
WheelAI
Analyze CI options with the wheel strategy
StockInsider
StockInsider
See market sentiment on CI